Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
*Potential value added to net returns based on a recent Vanguard study, "Putting a Value on Your Value: Quantifying Vanguard Advisor's Alpha." [Assumes a $100,000 starting portfolio and a 5% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results